Metformin Plus Insulin on Non-obese Autoimmune Diabetes
NCT ID: NCT03513874
Last Updated: 2020-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
15 participants
INTERVENTIONAL
2017-08-01
2021-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Metformin as add-on Therapy on Glycemic Control and Other Outcomes in Type 1 Diabetes
NCT03590262
the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin
NCT02438397
The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM
NCT02765347
Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes
NCT03194945
Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions
NCT00832481
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metformin + Insulin
Metformin
Patients will be subscribed with 850mg metformin orally twice daily. Insulin will be continued as routine therapy.
Insulin
Patients will continue insulin therapy following physicians' instructions.
Insulin alone
Insulin
Patients will continue insulin therapy following physicians' instructions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metformin
Patients will be subscribed with 850mg metformin orally twice daily. Insulin will be continued as routine therapy.
Insulin
Patients will continue insulin therapy following physicians' instructions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ageā„ 18 years and less than 70 years.
* Non-obese: defined as BMI less than 28 kg/m2
* Positive for at least one of the anti-islet autoantibodies: GADA, IA2A, ZnT8A
* Fasting or postprandial plasma C-peptide more than 100 pmol/L
* Written informed consent from the patient or family representative.
Exclusion Criteria
* Female patients who are pregnant or breastfeeding before or during the three-year follow-up
* Poor compliance or refusal to participate.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Xiangya Hospital of Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhiguang Zhou
Director, Department of Endocrinology, Institute of Metabolism and Endocrinology, National Clinical Research Center for Metabolic Diseases, Second Xiangya Hospital, Central South University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MET201801
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.